Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village

Journal of Infectious Diseases

Volumn 191, Issue 2, 2005, Pages 264-271

  Perrant, Ronald ^a,c   Marrama, Laurence ^a   Diouf, Babacar ^a   Sokhna, Cheikh ^a   Tall, Adama ^a   Nabeth, Pierre ^a   Trape, Jean François ^a   Longacre, Shirley ^b   Mercereau Puijalon, Odile ^b  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^b INSTITUT PASTEUR   (France)

^c INSTITUT PASTEUR DE DAKAR   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MEROZOITE SURFACE PROTEIN 1; PROTOZOON ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS; CHILD; ERYTHROCYTE; FEMALE; GROWTH INHIBITION; HUMAN; MALARIA; MALE; MEROZOITE; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SENEGAL; SEROLOGY;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CONSERVED SEQUENCE; HUMANS; IMMUNOGLOBULIN G; MALARIA; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDIES;

EID: 11844261511     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/426398     Document Type: Article

References (43)

1. Brown GV, Anders RF, Knowles G. Differential effect of immunoglobulin on the in vitro growth of several isolates of Plasmodium falciparum. Infect Immun 1983; 39:1228-35.
2. Chang SP, Gibson HL, Lee NC, Barr PJ, Hui GS. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol 1992; 149:548-55.
3. Lyon JA, Thomas AW, Hall T, Chulay JD. Specificities of antibodies that inhibit merozoite dispersal from malaria-infected erythrocytes. Mol Biochem Parasitol 1989; 36:77-85.
4. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of P. falciparum asexual blood stages. J Exp Med 1995; 182:409-18.
5. Celada A, Cruchaud A, Perrin LH. Opsonic activity of human immune serum on in vitro phagocytosis of Plasmodium falciparum infected red blood cells by monocytes. Clin Exp Immunol 1982; 47:635-44.
6. Groux H, Gysin J. Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: functional role of IgG subclasses. Res Immunol 1990; 141:529-42.
7. Qari SH, Shi YP, Goldman IF, Nahlen BL, Tibayrenc M, Lal AA. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. Mol Biochem Parasitol 1998; 92:241-52.
8. Jongwutiwes S, Tanabe K, Kanbara H. Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) of Plasmodium falciparum from field isolates. Mol Biochem Parasitol 1993; 59:95-100.
9. Blackman MJ, Ling IT, Nicholls SC, Holder AA. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol 1991; 49:29-33.
10. Chitarra V, Holm I, Bentley GA, Petres S, Longacre S. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. Mol Cell 1999; 3:457-64.
11. Pizarro JC, Chitarra V, Verger D, et al. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. J Mol Biol 2003; 328:1091-103.
12. Holder AA, Guevara Patino JA, Uthaipibull C, et al. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia 1999; 41:409-14.
13. Guevara Patino JA, Holder AA, McBride JS, Blackman MJ. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 1997; 186:1689-99.
14. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med 1994; 180:389-93.
15. de Koning-Ward TF, O'Donnell RA, Drew DR, Thomson R, Speed TP, Crabb BS. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J Exp Med 2003; 198:869-75.
16. Tolle R, Fruh K, Doumbo O, et al. A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections. Infect Immun 1993; 61:40-7.
17. Alyaman F, Genton B, Kramer KJ, et al. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg 1996; 54:443-8.
18. Egan AF, Morris J, Barnish G, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 1996; 173:765-9.
19. Shi YP, Sayed U, Qari SH, et al. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun 1996; 64:2716-23.
20. Branch OH, Udhayakumar V, Hightower AW, et al. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kilodalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg 1998; 58:211-9.
21. Conway DJ, Cavanagh DR, Tanabe K, et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 2000; 6:689-92.
22. Cavanagh DR, Elhassan IM, Roper C, et al. A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol 1998; 161:347-59.
23. Dodoo D, Theander TG, Kurtzhals JA, et al. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun 1999; 67:2131-7.
24. O'Donnell RA, de Koning-Ward TF, Burt RA, et al. Antibodies against merozoite surface protein (MSP)-1 (19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 2001; 193:1403-12.
25. Fontenille D, Lochouarn L, Diatta M, et al. Four years' entomological study of the transmission of seasonal malaria in Senegal and the bionomics of Anopheles gambiae and A. arabiensis. Trans Roy Soc Trop Med Hyg 1997; 91:647-52.
26. Trape J-F, Rogier C. Combating malaria morbidity and mortality by reducing transmission. Parasitol Today 1996; 12:236-40.
27. Trape JF, Pison G, Spiegel A, Enel C, Rogier C. Combating malaria in Africa. Trends Parasitol 2002; 18:224-30.
28. Egan AF, Chappel JA, Burghaus PA, et al. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun 1995; 63:456-66.
29. Locher CP, Tam LQ. Reduction of disuifide bonds in Plasmodium falciparum gp195 abolishes the production of growth-inhibitory antibodies. Vaccine 1993; 11:1119-23.
30. Trape JF, Rogier C, Konate L, et al. The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg 1994; 51:123-37.
31. Perraut R, Marrama L, Diouf B, et al. Distinct surrogate markers for protection against Plasmodium falciparum infection and clinical malaria identified in a Senegalese community after radical drug cure. J Infect Dis 2003; 188:1940-50.
32. Perraut R, Guillotte M, Drame I, et al. Evaluation of anti-Plasmodium falciparum antibodies in Senegalese adults using different types of crude extracts from various strains of parasite. Microbes Infect 2002; 4:31-5.
33. Holm I, Nato F, Mendis KN, Longacre S. Characterization of C-terminal merozoite surface protein-1 baculovirus recombinant proteins from Plasmodium vivax and Plasmodium cynomolgi as recognized by the natural anti-parasite immune response. Mol Biochem Parasitol 1997; 89:313-9.
34. Nguer CM, Diallo TO, Diouf A, et al. Plasmodium falciparum- and merozoite surface protein 1-specific antibody isotype balance in immune Senegalese adults. Infect Immun 1997; 65:4873-6.
35. Diouf B, Pradines B, Spiegel A, et al. Re-assessment of P. falciparum culture inhibition assays for the appraisal of immunity of individual living in endemic area of malaria transmission (author's transl). Dakar Med 2002; 47:5-11.
36. Schleiermacher D, Rogier C, Spiegel A, Tall A, Trape JF, Mercereau-Puijalon O. Increased multiplicity of Plasmodium falciparum infections and skewed distribution of individual msp1 and msp2 alleles during pregnancy in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Am J Trop Med Hyg 2001; 64:303-9.
37. Zwetyenga J, Rogier C, Spiegel A, Fontenille D, Trape JF, Mercereau-Puijalon O. A cohort study of Plasmodium falciparum diversity during the dry season in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Trans R Soc Trop Med Hyg 1999; 93:375-8.
38. Zwetyenga J, Rogier C, Tall A, et al. No influence of age on infection complexity and allelic distribution in Plasmodium falciparum infections in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Am J Trop Med Hyg 1998; 59:726-35.
39. Konate L, Zwetyenga J, Rogier C, et al. Variation of Plasmodium falciparum msp1 block 2 and msp2 allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions. Trans R Soc Trop Med Hyg 1999; 93(Suppl 1):21-8.
40. Riley EM, Allen SJ, Wheeler JG, et al. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 1992; 14:321-37.
41. Cavanagh DR, Dobano C, Elhassan IM, et al. Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozojte surface protein 1 of Plasmodium falciparum. Infect Immun 2001; 69:1207-11.
42. Blackman MJ, Holder AA. Use of a recombinant baculovirus product to measure naturally-acquired human antibodies to disulphide-constrained epitopes on the P. falciparum merozoite surface protein-1 (MSP1). FEMS Immunol Med Microbiol 1993; 6:307-15.
43. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998; 4:358-60.